发布求助
文献互助 智能选刊 最新文献

Current opinion in virology最新文献

筛选
英文 中文
From high-throughput to therapeutic: host-directed interventions against influenza viruses 从高通量到治疗性:针对流感病毒的宿主定向干预
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2021.12.014
Joseph D Trimarco , Nicholas S Heaton
{"title":"From high-throughput to therapeutic: host-directed interventions against influenza viruses","authors":"Joseph D Trimarco ,&nbsp;Nicholas S Heaton","doi":"10.1016/j.coviro.2021.12.014","DOIUrl":"10.1016/j.coviro.2021.12.014","url":null,"abstract":"<div><p><span>Influenza viruses are simultaneously supported and antagonized by factors within the host cell. This close relationship is the theoretical basis for future antivirals that target the host rather than the virus itself, a concept termed host-directed therapeutics. Genetic screening has led to the identification of host factors capable of modulating influenza </span>virus infections, and these factors represent candidate targets for host-directed antiviral strategies. Despite advances in understanding host targets, however, there are currently no host-directed interventions for influenza viruses in clinical use. In this brief review, we discuss some host factors identified in knockout/knockdown and overexpression screens that could potentially be targeted as host-directed influenza intervention strategies. We further comment on the feasibility of changing gene expression in the respiratory tract with RNA delivery vectors and transient CRISPR-mediated gene targeting.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world 噬菌体库作为发展中国家快速和经济有效地管理抗菌素耐药性的潜在工具
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101208
Tobi Nagel , Lillian Musila , Milkah Muthoni , Mikeljon Nikolich , Jesca L Nakavuma , Martha RJ Clokie
{"title":"Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world","authors":"Tobi Nagel ,&nbsp;Lillian Musila ,&nbsp;Milkah Muthoni ,&nbsp;Mikeljon Nikolich ,&nbsp;Jesca L Nakavuma ,&nbsp;Martha RJ Clokie","doi":"10.1016/j.coviro.2022.101208","DOIUrl":"10.1016/j.coviro.2022.101208","url":null,"abstract":"<div><p>Lower and middle-income countries seldom develop vaccines and therapeutics for their own populations and are dependent on supplies from industrialized countries, which are often hampered by financial or supply chain limitations. This has resulted in major delays in delivery with significant loss of life, as seen with the coronavirus pandemic. Since the vast majority of deaths from the antimicrobial resistance crisis are expected to occur in developing countries, there is an urgent need for in-country production of antibacterial therapies such as phages. Nationally controlled phage banks might provide such a solution since locally developed phage therapies tailored to endemic bacterial strains could offer cost-effective antibiotic alternatives.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9155372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
An overview of the current state of phage therapy for the treatment of biofilm-related infections 噬菌体治疗生物膜相关感染的现状综述
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101209
Diana P Pires , Luciana Meneses , Ana C Brandão , Joana Azeredo
{"title":"An overview of the current state of phage therapy for the treatment of biofilm-related infections","authors":"Diana P Pires ,&nbsp;Luciana Meneses ,&nbsp;Ana C Brandão ,&nbsp;Joana Azeredo","doi":"10.1016/j.coviro.2022.101209","DOIUrl":"10.1016/j.coviro.2022.101209","url":null,"abstract":"<div><p>Bacterial biofilms are involved in many chronic and difficult-to-treat infections. Phage therapy against infectious biofilms is becoming a promising strategy, as suggested by the increasing number of publications demonstrating the efficacy of phages against <em>in vitro</em> formed biofilms. However, the translation between <em>in vitro</em> results to <em>in vivo</em> phage therapy outcome is not straightforward due to the complexity of phage-biofilm interactions in clinical contexts. Here, we provide a critical overview of the <em>in vitro</em> studies of phages for biofilm control of clinical pathogens, followed by the major outcomes and lessons learned from the recently reported case studies (between 2018 and 2021) of phage therapy against biofilm-related infections.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625722000165/pdfft?md5=4f57bdc6057036abc1a6e00ba72a9b05&pid=1-s2.0-S1879625722000165-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44244846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing RNA病毒和cGAS-STING通路:重塑我们对先天免疫感知的理解
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101206
Laurence G Webb , Ana Fernandez-Sesma
{"title":"RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing","authors":"Laurence G Webb ,&nbsp;Ana Fernandez-Sesma","doi":"10.1016/j.coviro.2022.101206","DOIUrl":"10.1016/j.coviro.2022.101206","url":null,"abstract":"<div><p>The past decade has provided critical information about the cytoplasmic innate immune sensing pathway of cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING). These discoveries have broadened our understanding of the interconnectedness of the cGAS-STING pathway with autophagy, programmed cell death, Rig-I-like receptor (RLR) signaling, DNA independent interferon induction, and how this pathway responds to RNA virus infection. These advances highlight how multiple families of RNA viruses are restricted by and in turn have mechanisms to inhibit cGAS-STING dependent type-I interferon (IFN-I) induction. Here we review recent discoveries of how and why the cGAS-STING pathway responds to infection with RNA viruses, novel findings of RNA viral antagonism of the cGAS-STING innate immune sensing pathway, and attempt to provide context for a shift in thinking as to how critical this DNA sensing pathway is for the restriction of a wide range of RNA viruses.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187962572200013X/pdfft?md5=4aa0662173b2f513f95bb6679a729650&pid=1-s2.0-S187962572200013X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39935116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Advances in human monoclonal antibody therapy for HBV infection 人单克隆抗体治疗HBV感染的研究进展
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101205
Maxime Beretta , Hugo Mouquet
{"title":"Advances in human monoclonal antibody therapy for HBV infection","authors":"Maxime Beretta ,&nbsp;Hugo Mouquet","doi":"10.1016/j.coviro.2022.101205","DOIUrl":"10.1016/j.coviro.2022.101205","url":null,"abstract":"<div><p><span><span><span>HBV neutralizing antibodies target the </span>viral envelope antigens (HBsAg) and confer long-term immune protection in vaccinees and infected humans who seroconvert. They recognize various HBsAg epitopes, and can be armed with Fc-dependent effector functions essential for eliminating infected cells and stimulating </span>adaptive immunity<span>. Hundreds of HBsAg-specific monoclonal antibodies (mAbs) were produced from the early 80’s, but it is only recently that </span></span><em>bona fide</em> human anti-HBV mAbs were generated from vaccinees and seroconverters. Neutralizing HBV mAbs have <em>in vivo</em><span> prophylactic and therapeutic efficacy in animal models, and the capacity to decrease antigenemia and viremia<span> in infected humans. Thus, polyfunctional, potent and broad human HBV neutralizing mAbs offer novel opportunities to develop effective interventions to prevent and treat HBV infection. Here, we summarize recent findings on the humoral immune response to HBV, and explore the potential of human HBV neutralizing mAbs as immunotherapeutics to help achieving a functional cure for HBV.</span></span></p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39753468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses 抗高致病性冠状病毒的中和单克隆抗体
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2021.12.015
Rong Xiang , Yang Wang , Lili Wang , Xiaoqian Deng , Shanshan Huo , Shibo Jiang , Fei Yu
{"title":"Neutralizing monoclonal antibodies against highly pathogenic coronaviruses","authors":"Rong Xiang ,&nbsp;Yang Wang ,&nbsp;Lili Wang ,&nbsp;Xiaoqian Deng ,&nbsp;Shanshan Huo ,&nbsp;Shibo Jiang ,&nbsp;Fei Yu","doi":"10.1016/j.coviro.2021.12.015","DOIUrl":"10.1016/j.coviro.2021.12.015","url":null,"abstract":"<div><p>The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10694772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy 抗狂犬病单克隆抗体:目前在预防和治疗中的应用
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101204
Guilherme Dias de Melo , Jan Hellert , Rajesh Gupta , Davide Corti , Hervé Bourhy
{"title":"Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy","authors":"Guilherme Dias de Melo ,&nbsp;Jan Hellert ,&nbsp;Rajesh Gupta ,&nbsp;Davide Corti ,&nbsp;Hervé Bourhy","doi":"10.1016/j.coviro.2022.101204","DOIUrl":"10.1016/j.coviro.2022.101204","url":null,"abstract":"<div><p>Rabies is a severe viral infection that causes an acute encephalomyelitis, which presents a case fatality of nearly 100% after the manifestation of neurological clinical signs. Rabies can be efficiently prevented with post-exposure prophylaxis (PEP), composed of vaccines and anti-rabies immunoglobulins (RIGs); however, no treatment exists for symptomatic rabies. The PEP protocol faces access and implementation obstacles in resource-limited settings, which could be partially overcome by substituting RIGs for monoclonal antibodies (mAbs). mAbs offer lower production costs, consistent supply availability, long-term storage/stability, and an improved safety profile. Here we summarize the key features of the different available mAbs against rabies, focusing on their application in PEP and highlighting their potential in a novel therapeutic approach.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625722000116/pdfft?md5=f129e04c5554a8994f4c77c223e81f8c&pid=1-s2.0-S1879625722000116-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39774081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Evolution of the interferon response: lessons from ISGs of diverse mammals 干扰素反应的进化:来自不同哺乳动物isg的经验教训
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101202
Matthew B McDougal, Ian N Boys , Pamela De La Cruz-Rivera, John W Schoggins
{"title":"Evolution of the interferon response: lessons from ISGs of diverse mammals","authors":"Matthew B McDougal,&nbsp;Ian N Boys ,&nbsp;Pamela De La Cruz-Rivera,&nbsp;John W Schoggins","doi":"10.1016/j.coviro.2022.101202","DOIUrl":"10.1016/j.coviro.2022.101202","url":null,"abstract":"<div><p><span>The vertebrate interferon (IFN) response controls </span>viral infections<span> by inducing hundreds of interferon-stimulated genes (ISGs), many of which encode ‘restriction factors’ that uniquely target certain viruses<span>. ISG studies have historically had a human-centric focus, which is justified because these natural defense mechanisms might be leveraged to treat human viral disease. However, certain mammals are reservoirs for zoonotic viruses that can ‘spill over’ into humans. Additionally, restriction factors have prominent roles in the ongoing evolutionary genetic conflicts between viruses and their hosts. Thus, there is a growing need to understand antiviral IFN/ISG responses in other species, particularly in known reservoirs of zoonotic viruses. This review focuses on functional and evolutionary insight into antiviral IFN responses that have been obtained from studying non-model mammalian species.</span></span></p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39595641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
A structural view of the SARS-CoV-2 virus and its assembly SARS-CoV-2病毒及其组装的结构视图
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-02-01 DOI: 10.1016/j.coviro.2021.11.011
Nathan J Hardenbrook , Peijun Zhang
{"title":"A structural view of the SARS-CoV-2 virus and its assembly","authors":"Nathan J Hardenbrook ,&nbsp;Peijun Zhang","doi":"10.1016/j.coviro.2021.11.011","DOIUrl":"10.1016/j.coviro.2021.11.011","url":null,"abstract":"<div><p>The SARS-CoV-2 pandemic that struck in 2019 has left the world crippled with hundreds of millions of cases and millions of people dead. During this time, we have seen unprecedented support and collaboration amongst scientists to respond to this deadly disease. Advances in the field of structural biology, in particular cryoEM and cryo-electron tomography, have allowed unprecedented structural analysis of SARS-CoV-2. Here, we review the structural work on the SARS-CoV-2 virus and viral components, as well as its cellular assembly process, highlighting some important structural findings that have made significant impact on the protection from and treatment of emerging viral infections.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39593503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
Editorial overview: Virus bioinformatics - empowering genomics of pathogens, viromes, and the virosphere across divergence scales 编辑概述:病毒生物信息学-增强病原体、病毒组和病毒圈跨差异尺度的基因组学能力
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-02-01 DOI: 10.1016/j.coviro.2021.12.001
Alexander E Gorbalenya , Maria Anisimova
{"title":"Editorial overview: Virus bioinformatics - empowering genomics of pathogens, viromes, and the virosphere across divergence scales","authors":"Alexander E Gorbalenya ,&nbsp;Maria Anisimova","doi":"10.1016/j.coviro.2021.12.001","DOIUrl":"10.1016/j.coviro.2021.12.001","url":null,"abstract":"","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39753482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信